BioNTech CEO Ugur Sahin Sells $8.44M in Ordinary Shares via Rule 10b5-1 Plan

Executive Summary

On September 14, 2026, BioNTech SE (NASDAQ: BNTX) reported Form 4 transactions executed by its Chief Executive Officer and 10% Owner, Ugur Sahin. Over two trading days (September 11 and September 14, 2026), Dr. Sahin disposed of an aggregate of 86,000 ordinary shares generating gross proceeds of approximately $8.44 million.

---

Transaction Breakdown

• September 11, 2026: Sold 45,000 shares at a weighted-average price of $96.9338 per share ($4,362,021.00).
• September 14, 2026: Sold 41,000 shares at a weighted-average price of $99.4467 per share ($4,077,314.70).
• Total Disposed: 86,000 Ordinary Shares
• Blended Execution Price: ~$98.13
• Gross Value Realized: $8,439,335.70

---

Ownership Structure & Context

1. Direct Ownership: Following the transactions, Dr. Sahin directly retains 602,209 ordinary shares.
2. Indirect Ownership: Dr. Sahin maintains indirect ownership of 39,218,111 ordinary shares through Medine GmbH (of which he is the sole shareholder).
3. Portfolio Impact: The 86,000 shares sold represent roughly 0.22% of Dr. Sahin's total combined direct and indirect equity stake (>39.8 million shares), leaving his vast majority holding intact.
4. Pre-Arranged Plan: The dispositions were executed pursuant to a pre-scheduled Rule 10b5-1 trading plan established on June 3, 2026, mitigating concerns regarding discretionary insider selling.